Clinical Research and Trials-A "Nonessential" Victim of the COVID-19 Pandemic?

"CONFLICTS OF INTEREST Guarantor of the article: Ashwin N. Ananthakrishnan, MD. Specific author contributions: Both authors contributed equally to the manuscript. Financial support: None to report. Potential competing interests: A.N.A. has served on advisory boards for Kyn Therapeutics and Sun Pharma. L.P.-B. has received personal fees from AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boehringer Ingelheim, Pfizer, InDex Pharmaceuticals, Sandoz, Celgene, Biogen, Samsungbioepis, Alma, Sterna, Nestle, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance, grants from Abbvie, MSD, Takeda, and stock options from CTMA."

"Financial support: None to report."